Tillman U. Gerngross, Ph.D.

Bio

Tillman U. Gerngross, Ph.D. is our co-founder and has served as a member of our board of directors and as our chief executive officer since June 2020. Dr. Gerngross is a founder, director and executive officer of numerous biotechnology companies. He is a co-founder of Adimab, LLC and has served as its chief executive officer and as a director since 2007. He is also a co-founder and chairman of Avitide, Inc. since August 2012, a co-founder and chairman of Alector, Inc. since September 2017, a co-founder, president and chairman of Amagma, Inc. since August 2019 and a co-founder, president and chairman of Ankyra Therapeutics, Inc. since November 2019.

Dr. Gerngross is currently a venture partner at SV Life Sciences Advisors, LLC, which he joined in 2006. Dr. Gerngross co-founded GlycoFi, Inc. and served as its chief scientific officer from 2000 to 2006 until it was acquired by Merck & Company, Inc. Dr. Gerngross currently teaches at the Thayer School of Engineering, at Dartmouth College, where he has taught since 1998. Dr. Gerngross received a B.S. and M.S. in chemical engineering and a Ph.D. in molecular biology from Technical University of Vienna.

Robert Allen, Ph.D.

Robert Allen joined Invivyd in April of 2023 as our Chief Scientific Officer. He brings over 30 years of experience across the infectious disease space, most recently as the Chief Scientific Officer of SmartPharm Therapeutics, a subsidiary of Sorrento Therapeutics, from 2020 to 2023. During that time, he led efforts to develop gene-encoded monoclonal antibodies for COVID-19 that could be quickly adapted to respond to emerging variants of concern. Prior to his time at SmartPharm Therapeutics, he held multiple senior scientific roles across the pharmaceutical and biotechnology industries including Sorrento Therapeutics, SIGA Technologies, and the Oregon Translational Research and Development Institute. Robert holds a Ph.D. in Microbiology from Columbia University, an M.S. in Applied Biology from Georgia Institute of Technology, and a B.S. in Biology from Rhodes College. He has published extensively in the field of virology and completed his postdoctoral training in virology at Washington University in St. Louis and Emory University.

Becky Dabora, Ph.D.

Rebecca Dabora, Ph.D. has served as our Chief Technology & Manufacturing Officer since July 2020. In addition, Dr. Dabora is currently serving as principal for RDBio Consulting LLC since July 2005. Prior to joining Invivyd, Dr. Dabora served as interim chief technology officer of SwanBio Therapeutics, Inc. from July 2019 to July 2020 and chief technology officer of Aspyrian Therapeutics, Inc. from March 2016 to March 2017. Dr. Dabora received a B.A. in biochemistry from Bowdoin College and a Ph.D. in applied biological sciences and biochemical engineering from the Massachusetts Institute of Technology.

Lynn Connolly, M.D., Ph.D.

Bio

Lynn Connolly, M.D., Ph.D. has served as our chief medical officer since July 2020. Prior to joining Adagio, Dr. Connolly served as senior vice president, clinical research from March 2020 to July 2020 and vice president, clinical research from March 2018 to February 2020 of Vir Biotechnology, Inc. Dr. Connolly served as vice president and head of late development from January 2017 to March 2018 and senior medical director from January 2016 to January 2017 of Achaogen, Inc. Dr. Connolly received a B.A. in molecular biology from University of California, Berkeley and a M.D. and Ph.D. in cell biology from University of California, San Francisco.

Fred Driscoll

Fred is our interim Chief Financial Officer. He brings over 20 years of experience in financial management of life sciences companies, most recently as the Chief Financial Officer at Renovacor. Prior to Renovacor, he was Chief Financial Officer at Flexion Therapeutics, where he spearheaded an initial public offering in 2014. Before that, Fred served as Chief Financial Officer at Novavax from 2009 to 2013. From 2007 to 2009, he served as first the CFO and then the CEO of Genelabs Technologies, a publicly traded biopharmaceutical and diagnostics company later acquired by GlaxoSmithKline. From 2000 to 2006, he served as Chief Executive Officer at OXiGENE, where he also served as Chairman of the Board and Audit Committee Chair. He is a member of the Board of Directors and Chair of the Audit Committees for Cue Biopharma, Cellectar Biosciences, and MEI Pharma. He holds a B.S. in Accounting and Finance from Bentley University.

David Hering, M.B.A.

Dave is our Chief Executive Officer and a member of Invivyd’s Board of Directors. He joined in July of 2021, first serving as Chief Operating Officer before moving into the CEO role in February of 2022. Prior to joining the Invivyd team, Dave held a variety of leadership roles in his six years at Pfizer, where he led the preparation and launch of Pfizer’s COVID-19 vaccine in the United States, including the initial contracts with the U.S. government. He also led Pfizer’s partnership with Gavi, the Vaccine Alliance, which supplies millions of vaccines to the developing world.  Before Pfizer, Dave held several roles at Novartis, most notably serving on the front lines of the H1N1 Pandemic and leading the Medical Counter Measures group. He holds an M.B.A. from Harvard Business School and a B.S. in Operations Research and Industrial Engineering from Cornell University.

Elham (Ellie) Hershberger, Pharm.D.

Elham (Ellie) Hershberger, Pharm.D. has served as our chief development officer since June 2020. Prior to joining Invivyd, Dr. Hershberger served as president of EMH Consulting Group, Inc. from July 2017 to October 2020 and as head of clinical development of Visterra, Inc. from January 2016 to July 2017. Dr. Hershberger received a B.S. in chemistry from University of Minnesota and a Pharm.D. from Ferris State University.

Pete Schmidt, M.D., M.S.

Pete is our Chief Medical Officer. He joined Invivyd in November of 2020, first serving as the Vice President of Clinical Research before being appointed CMO in December of 2022. He brings nearly 15 years of experience in drug discovery to the team, having overseen both early and late-stage clinical development programs, as well as supporting key regulatory activities and filings. Prior to joining Invivyd, Pete worked in academic research and therapeutics development for neurology, pain, and respiratory products. He is an Assistant Clinical Professor in the Division of Pain Medicine at the Stanford University School of Medicine. He holds an M.D. from the University of Colorado School of Medicine, an M.S. in Epidemiology and Clinical Research from Stanford University, and a B.A. in Psychology from Cornell University.

Jeremy Gowler

Jeremy joined Invivyd in December of 2022 as Chief Operating and Commercial Officer. He brings over 20 years of experience across multiple key functions, including marketing, sales, business development, and medical affairs, and has commercial experience in all phases of the product lifecycle from early clinical development to launch to maturity. Prior to joining Invivyd, Jeremy served as the global commercial head of the biopharma business unit in Sandoz, where he was responsible for the launch of late-stage pipeline assets as well as their commercial portfolio. Before his time at Sandoz, he held multiple senior commercial roles across the pharmaceutical and biotechnology industry. He holds a Diploma of Technology from The British Colombia Institute of Technology and a B.S. in Biology and Environmental Studies from the University of Victoria.

Eric Kimble, M.B.A.

Eric Kimble, MBA has served as chief commercial officer since September 2020. Prior to joining Invivyd, Mr. Kimble served as chief commercial officer for Entasis Therapeutics, Inc. from April 2019 to September 2020 and as a consultant for various emerging biotechnology companies from June 2013 to April 2019. Mr. Kimble received an A.B. in English literature and business economics from Brown University and an MBA from the Harvard Business School.

Jill Andersen, J.D.

Jill has served as Chief Legal Officer and Corporate Secretary since joining Invivyd in November of 2021. She has worked extensively on matters related to product development, marketing approval, and commercialization, including product launches across multiple therapeutic areas. Her experience also spans corporate governance, securities, corporate transactions, IP, litigation, and investigations. Jill has spent over 15 years in the pharmaceutical and biotechnology industries, most recently at Oyster Point Pharma where she served as General Counsel, Corporate Secretary, and Chief Compliance Officer. She holds a J.D. from Wake Forest University and a B.S. in Finance from Boston College.

Kyra Rosow Faircloth, M.S.

Kyra Rosow Faircloth is our Vice President of Government Affairs, Advocacy and Corporate Communications. She joined us in October of 2022 to lead our integrated approach to patient engagement, public health policy, communications, and media relations. Prior to joining the Invivyd team, she held a variety of leadership roles in her nearly 15 years at Pfizer, including serving as the US commercial lead for Pfizer’s COVID-19 vaccine launch. Though her role encompasses a broad range of responsibilities, Kyra notes that her favorite part of the job is coordinating the development of legislative and regulatory strategies to advocate for Invivyd’s goals and influence action plans. She holds an M.S. in Global Health from Northwestern University and a B.A. in English Pre-Law from Virginia Tech University.

Heidi Spurling, M.S.

Heidi Spurling serves as our Vice President of Strategy and Operations and Chief of Staff to the CEO. One of our earliest employees, she joined in August of 2020 and served as the program management lead for the adintrevimab program. With over 20 years of experience in the pharmaceutical and biotechnology industry, spanning a variety of areas and phases of the product life cycle, Heidi brings both depth and breadth of expertise to the team. For the decade prior to joining Invivyd, she worked for Ironwood Pharmaceuticals, serving in several program management and corporate strategy positions. She holds an M.S. in Management from Boston University and a B.S. in Microbiology from the University of Maine.

Julie Green, M.B.A.

Julie Green is our Senior Vice President of Human Resources. She joined Invivyd in January of 2022 to provide strategic leadership on people matters while directing key initiatives for the Invivyd workforce. Specializing in fast-paced and high growth environments, Julie has demonstrated her passion for fostering connections, differentiating the employee experience and ultimately making a difference for patients and their families during her more than 25 years of human resources experience. Prior to joining Invivyd she was Vice President of Human Resources at Flexion Therapeutics from 2018 to 2022. From 2012 to 2018, she started and led her own HR consulting firm offering strategic advice and HR solutions to a variety of organizations, specializing in the life science space. She holds an M.B.A. from Babson College and a B.S. in Psychology from Union College.

Stacy Price, M.S.

Stacy Price joined Invivyd in March of 2023 as our Chief Technology and Manufacturing Officer. She brings over 25 years of experience in commercial and clinical biotechnology operations management, most recently as the Chief Technical Officer at Akouos from 2021 to 2023. During that time, she established the technical operations strategy to support multiple AAV combination gene therapy programs and contributed to the completion and approval of an IND. Prior to that, she spent four years at Ziopharm Oncology as Senior Vice President of Technical Operations, where she was responsible for the development and delivery of CMC strategy as well as the facilities construction of a research and manufacturing site for cell and combination gene therapy products. Before Ziopharm, she held multiple manufacturing and operational roles of increasing responsibility across the pharmaceutical and biotechnology industry. She holds an M.S. in Biochemical Engineering and a B.S. in Chemical Engineering from Tufts University.

Terry McGuire

Bio

Terrance McGuire has served as a member of our board of directors since October 2020. Mr. McGuire has extensive expertise in the biotechnology industry, having spent his career in venture capital and as a director of several biotechnology companies. Mr. McGuire is a founding partner of Polaris Partners, a venture capital firm investing in technology and healthcare companies, since 1996. In addition, Mr. McGuire also currently serves on the boards of directors of Cyclerion Therapeutics since 2019, Seer since 2017, Alector since 2013 , and Adimab, LLC since August 2007. Mr. McGuire received a B.S. in physics and economics from Hobart College, an MBA from Harvard Business School and an M.S. in engineering from the Thayer School at Dartmouth College. 

Tom Heyman

Bio

Tom Heyman has served as a member of our board of directors since June 2021. Mr. Heyman previously served as the president of Johnson & Johnson’s Corporate Venture Capital Group from April 2015 to September 2019 and as the global head of business development for Johnson & Johnson’s Pharmaceutical Group from March 1992 to March 2015. In addition, Mr. Heyman previously served as chief executive officer of Janssen Pharmaceuticals from November 2008 to November 2016. Mr. Heyman has served as a director of OptiNose, Inc. since December 2020 and a director of Akero Therapeutics, Inc. since June 2020. Mr. Heyman received his Master of Laws from Katholieke Universiteit Leuven.

Michael Wyzga

Bio

Michael Wyzga is the president of MSW Consulting, Inc., a private company focused on strategic biotechnology consulting, a position he has held since November 2013. Prior to that, he served as president, chief executive officer and a member of the board of directors of Radius Health, Inc. From 1993 to 2011, Mr. Wyzga served in various senior management positions at Genzyme Corporation, including as executive vice president, finance and as chief financial officer. During his time with Genzyme, Mr. Wyzga played key roles in the successful development and commercialization of a number of important therapies, including Cerezyme for Gauche disease, Fabrazyme for Fabry’s disease, Renagel for use in the treatment of dialysis patients and Campath for chronic lymphocytic leukemia. Mr. Wyzga has served on a number of public company boards, including at Mereo BioPharma Group plc, OncoMed Pharmaceuticals, Inc., X4 Pharmaceuticals, GenSight Biologics, LogicBio Therapeutics, Akebia Therapeutics, Inc., Idenix Pharmaceuticals, Inc., Prosensa Holding B.V. Mr. Wyzga received an MBA from Providence College and a B.S. from Suffolk University.

Christine Lindenboom

Bio

Ms. Lindenboom currently serves as the Senior Vice President, Investor Relations and Corporate Communications of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a biopharmaceutical company, where she has been employed since September 2015. Prior to Alnylam, Ms. Lindenboom served as Senior Director, Corporate Affairs for Pfizer, Inc. (NYSE: PFE), a multinational pharmaceutical and biotechnology corporation, from December 2013 to September 2015. Earlier in her career, Ms. Lindenboom served in various positions at Amgen, Inc. (NASDAQ: AMGN), a multinational biopharmaceutical company, from April 2006 to November 2013, most recently serving as Director, Media Relations, Global Communications and Philanthropy at the time of her departure. Ms. Lindenboom currently serves on the board of directors of Kendall Square Association, an internationally recognized innovation district located in Cambridge, MA. Ms. Lindenboom received a B.A. from Northeastern University.

Tamsin Berry

Bio

Tamsin Berry has served as a partner at Population Health Partners, a global investment firm, since June 2020. Since November 2021, she has served as non-executive director, and also as a board member, of the Global Pathogen Analysis Service, a not-for-profit pathogen surveillance bioinformatics company. Since March 2021, she has served as an advisor to EQRx, a biotechnology firm. Since December 2020, she has served as advisor to University of Oxford for the Global Health Security Consortium, which includes University of Oxford, the Tony Blair Institute and the Ellison Institute of Transformative Medicine. From February 2019 to March 2020, she served as the director of the UK Office for Life Sciences, where she worked with Sir John Bell to write the UK’s Life Sciences Industrial Strategy. She previously served as Deputy Director of the UK Office for Life Sciences, from November 2015 to February 2019. Ms. Berry has held a number of leadership positions in government, spanning policy, corporate, and communications roles at the Cabinet Office, Department of Health, and Public Health England. From March 2020 to June 2020, her final role was in the COVID Taskforce, where Ms. Berry was the senior responsible officer for serology and seroprevalence at the start of the pandemic and was awarded an OBE for her work. Ms. Berry received a bachelor of laws degree from the University of Nottingham and a master’s degree from the University of Leeds.

Marc Elia

Bio

Marc Elia has served as the founder and chief investment officer of M28 Capital Management L.P., a healthcare sector investment fund, since September 2019. Prior to that, from January 2012 to September 2019, Mr. Elia served as a partner at Bridger Capital, an investment fund. Mr. Elia serves on the board of directors of SQZ Biotechnology, a clinical-stage biotechnology company, and Fractyl Health Inc., an organ editing metabolic therapeutics company. Prior to his career in investing, Mr. Elia held various roles across the biotechnology industry at N30 Pharmaceuticals, Chiron Corporation, and L.E.K. Consulting. Mr. Elia served as a director of the Company from July 2020 to April 2021. Mr. Elia holds a B.A. in Economics from Carleton College.

Clive A. Meanwell, M.D.

Bio

Clive Meanwell, MB, CHB, MD is Executive Chair and Founder of Population Health Partners (‘PHP’), a global investment firm. Clive is Chief Executive of Population Health Investment Corporation (PHIC), a special purpose acquisition company created by PHP. He is also Vice Chairman of BB Biotech, the Swiss investment corporation, and a board member of EQRx. In association with PHP’s private investments, Clive is a board member of Comanche Biopharma, Fractyl Health and Hugo Health. Previously, Clive was the founder, and at various times, Executive Chairman, President, Chief Executive Officer and Chief Innovation Officer of The Medicines Company. Prior to that, he was a Partner at MPM Capital, and before then, he held senior global executive positions with the Roche Group. He trained in medicine, with post-graduate specialization in cancer treatment, cancer research, clinical trials, statistics, and epidemiology. He holds MB ChB and MD cum laude degrees from the University of Birmingham, UK.